Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 86


Response rates to single-agent chemotherapy after exposure to immune checkpoint inhibitors in advanced non-small cell lung cancer.

Schvartsman G, Peng SA, Bis G, Lee JJ, Benveniste MFK, Zhang J, Roarty EB, Lacerda L, Swisher S, Heymach JV, Fossella FV, William WN.

Lung Cancer. 2017 Oct;112:90-95. doi: 10.1016/j.lungcan.2017.07.034. Epub 2017 Aug 3.


Distinct pattern of TP53 mutations in human immunodeficiency virus-related head and neck squamous cell carcinoma.

Gleber-Netto FO, Zhao M, Trivedi S, Wang J, Jasser S, McDowell C, Kadara H, Zhang J, Wang J, William WN Jr, Lee JJ, Nguyen ML, Pai SI, Walline HM, Shin DM, Ferris RL, Carey TE, Myers JN, Pickering CR; Head and Neck Cancer Specialized Program of Research Excellence (SPORE) Human Immunodeficiency Virus (HIV) Supplement Consortium.

Cancer. 2018 Jan 1;124(1):84-94. doi: 10.1002/cncr.31063. Epub 2017 Oct 20.


PD-1 Blockade Prevents the Development and Progression of Carcinogen-Induced Oral Premalignant Lesions.

Wang J, Xie T, Wang B, William WN Jr, Heymach JV, El-Naggar AK, Myers JN, Caulin C.

Cancer Prev Res (Phila). 2017 Dec;10(12):684-693. doi: 10.1158/1940-6207.CAPR-17-0108. Epub 2017 Oct 10.


Gefitinib for patients with incurable cutaneous squamous cell carcinoma: A single-arm phase II clinical trial.

William WN Jr, Feng L, Ferrarotto R, Ginsberg L, Kies M, Lippman S, Glisson B, Kim ES.

J Am Acad Dermatol. 2017 Dec;77(6):1110-1113.e2. doi: 10.1016/j.jaad.2017.07.048. Epub 2017 Sep 28.


Prognostic biomarkers in patients with human immunodeficiency virus-positive disease with head and neck squamous cell carcinoma.

Zhang H, Kim S, Chen Z, Nannapaneni S, Chen AY, Moore CE, Sica G, Mosunjac M, Nguyen MLT, D'Souza G, Carey TE, Peterson LA, McHugh JB, Graham M, Komarck CM, Wolf GT, Walline HM, Bellile E, Riddell J 4th, Pai SI, Sidransky D, Westra WH, William WN Jr, Lee JJ, El-Naggar AK, Ferris RL, Seethala R, Grandis JR, Chen ZG, Saba NF, Shin DM; Head and Neck Cancer SPORE HIV supplement consortium.

Head Neck. 2017 Dec;39(12):2433-2443. doi: 10.1002/hed.24911. Epub 2017 Sep 25.


Outcomes of oral cavity cancer patients treated with surgery followed by postoperative intensity modulated radiation therapy.

Quinlan-Davidson SR, Mohamed ASR, Myers JN, Gunn GB, Johnson FM, Skinner H, Beadle BM, Gillenwater AM, Phan J, Frank SJ, William WN, Wong AJ, Lai SY, Fuller CD, Morrison WH, Rosenthal DI, Garden AS.

Oral Oncol. 2017 Sep;72:90-97. doi: 10.1016/j.oraloncology.2017.07.002. Epub 2017 Jul 16.


TCR Repertoire Intratumor Heterogeneity in Localized Lung Adenocarcinomas: An Association with Predicted Neoantigen Heterogeneity and Postsurgical Recurrence.

Reuben A, Gittelman R, Gao J, Zhang J, Yusko EC, Wu CJ, Emerson R, Zhang J, Tipton C, Li J, Quek K, Gopalakrishnan V, Chen R, Vence LM, Cascone T, Vignali M, Fujimoto J, Rodriguez-Canales J, Parra ER, Little LD, Gumbs C, Forget MA, Federico L, Haymaker C, Behrens C, Benzeno S, Bernatchez C, Sepesi B, Gibbons DL, Wargo JA, William WN Jr, Swisher S, Heymach JV, Robins H, Lee JJ, Sharma P, Allison JP, Futreal PA, Wistuba II, Zhang J.

Cancer Discov. 2017 Oct;7(10):1088-1097. doi: 10.1158/2159-8290.CD-17-0256. Epub 2017 Jul 21.


Facilitating anaplastic thyroid cancer specialized treatment: A model for improving access to multidisciplinary care for patients with anaplastic thyroid cancer.

Cabanillas ME, Williams MD, Gunn GB, Weitzman SP, Burke L, Busaidy NL, Ying AK, Yiin YH, William WN, Lu C, Lai SY.

Head Neck. 2017 Jul;39(7):1291-1295. doi: 10.1002/hed.24784. Epub 2017 Apr 28.


DNA methylation intratumor heterogeneity in localized lung adenocarcinomas.

Quek K, Li J, Estecio M, Zhang J, Fujimoto J, Roarty E, Little L, Chow CW, Song X, Behrens C, Chen T, William WN, Swisher S, Heymach J, Wistuba I, Zhang J, Futreal A, Zhang J.

Oncotarget. 2017 Mar 28;8(13):21994-22002. doi: 10.18632/oncotarget.15777.


Metabolic interrogation as a tool to optimize chemotherapeutic regimens.

Sandulache VC, Chen Y, Feng L, William WN, Skinner HD, Myers JN, Meyn RE, Li J, Mijiti A, Bankson JA, Fuller CD, Konopleva MY, Lai SY.

Oncotarget. 2017 Mar 14;8(11):18154-18165. doi: 10.18632/oncotarget.15186.


Patterns of Treatment Failure in Anaplastic Thyroid Carcinoma.

Rao SN, Zafereo M, Dadu R, Busaidy NL, Hess K, Cote GJ, Williams MD, William WN, Sandulache V, Gross N, Gunn GB, Lu C, Ferrarotto R, Lai SY, Cabanillas ME.

Thyroid. 2017 May;27(5):672-681. doi: 10.1089/thy.2016.0395. Epub 2017 Feb 16.


Recurrent oral cavity cancer: Patterns of failure after salvage multimodality therapy.

Quinlan-Davidson SR, Morrison WH, Myers JN, Gunn GB, William WN Jr, Beadle BM, Skinner HD, Gillenwater AM, Frank SJ, Phan J, Johnson FM, Fuller CD, Zafereo ME, Rosenthal DI, Garden AS.

Head Neck. 2017 Apr;39(4):633-638. doi: 10.1002/hed.24666. Epub 2016 Dec 22.


Activating NOTCH1 Mutations Define a Distinct Subgroup of Patients With Adenoid Cystic Carcinoma Who Have Poor Prognosis, Propensity to Bone and Liver Metastasis, and Potential Responsiveness to Notch1 Inhibitors.

Ferrarotto R, Mitani Y, Diao L, Guijarro I, Wang J, Zweidler-McKay P, Bell D, William WN Jr, Glisson BS, Wick MJ, Kapoun AM, Patnaik A, Eckhardt G, Munster P, Faoro L, Dupont J, Lee JJ, Futreal A, El-Naggar AK, Heymach JV.

J Clin Oncol. 2017 Jan 20;35(3):352-360. doi: 10.1200/JCO.2016.67.5264. Epub 2016 Nov 21.


Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled, phase 2 study.

Gomez DR, Blumenschein GR Jr, Lee JJ, Hernandez M, Ye R, Camidge DR, Doebele RC, Skoulidis F, Gaspar LE, Gibbons DL, Karam JA, Kavanagh BD, Tang C, Komaki R, Louie AV, Palma DA, Tsao AS, Sepesi B, William WN, Zhang J, Shi Q, Wang XS, Swisher SG, Heymach JV.

Lancet Oncol. 2016 Dec;17(12):1672-1682. doi: 10.1016/S1470-2045(16)30532-0. Epub 2016 Oct 24.


Real-Time Genomic Characterization Utilizing Circulating Cell-Free DNA in Patients with Anaplastic Thyroid Carcinoma.

Sandulache VC, Williams MD, Lai SY, Lu C, William WN, Busaidy NL, Cote GJ, Singh RR, Luthra R, Cabanillas ME.

Thyroid. 2017 Jan;27(1):81-87. doi: 10.1089/thy.2016.0076. Epub 2016 Nov 29.


Genomic heterogeneity of multiple synchronous lung cancer.

Liu Y, Zhang J, Li L, Yin G, Zhang J, Zheng S, Cheung H, Wu N, Lu N, Mao X, Yang L, Zhang J, Zhang L, Seth S, Chen H, Song X, Liu K, Xie Y, Zhou L, Zhao C, Han N, Chen W, Zhang S, Chen L, Cai W, Li L, Shen M, Xu N, Cheng S, Yang H, Lee JJ, Correa A, Fujimoto J, Behrens C, Chow CW, William WN, Heymach JV, Hong WK, Swisher S, Wistuba II, Wang J, Lin D, Liu X, Futreal PA, Gao Y.

Nat Commun. 2016 Oct 21;7:13200. doi: 10.1038/ncomms13200.


Reply to radiotherapy for human papillomavirus-positive oropharyngeal cancers in the National Cancer Data Base.

Garden AS, Fuller CD, Rosenthal DI, William WN Jr, Gunn GB, Beadle BM, Johnson FM, Morrison WH, Phan J, Frank SJ, Kies MS, Sturgis EM.

Cancer. 2016 Nov 15;122(21):3411-3412. doi: 10.1002/cncr.30193. Epub 2016 Jul 15. No abstract available.


Reirradiation of Head and Neck Cancers With Intensity Modulated Radiation Therapy: Outcomes and Analyses.

Takiar V, Garden AS, Ma D, Morrison WH, Edson M, Zafereo ME, Gunn GB, Fuller CD, Beadle B, Frank SJ, William WN Jr, Kies M, El-Naggar AK, Weber R, Rosenthal DI, Phan J.

Int J Radiat Oncol Biol Phys. 2016 Jul 15;95(4):1117-31. doi: 10.1016/j.ijrobp.2016.03.015. Epub 2016 Mar 19.


Prognostic factors, predictive markers and cancer biology: the triad for successful oral cancer chemoprevention.

Monteiro de Oliveira Novaes JA, William WN Jr.

Future Oncol. 2016 Oct;12(20):2379-86. doi: 10.2217/fon-2016-0168. Epub 2016 Jun 22. Review.


Reirradiation of Head and Neck Cancers With Proton Therapy: Outcomes and Analyses.

Phan J, Sio TT, Nguyen TP, Takiar V, Gunn GB, Garden AS, Rosenthal DI, Fuller CD, Morrison WH, Beadle B, Ma D, Zafereo ME, Hutcheson KA, Kupferman ME, William WN Jr, Frank SJ.

Int J Radiat Oncol Biol Phys. 2016 Sep 1;96(1):30-41. doi: 10.1016/j.ijrobp.2016.03.053. Epub 2016 Apr 13.


Eye-sparing multidisciplinary approach for the management of lacrimal gland carcinoma.

Esmaeli B, Yin VT, Hanna EY, Kies MS, William WN Jr, Bell D, Frank SJ.

Head Neck. 2016 Aug;38(8):1258-62. doi: 10.1002/hed.24433. Epub 2016 Mar 29.


Radiation therapy (with or without neck surgery) for phenotypic human papillomavirus-associated oropharyngeal cancer.

Garden AS, Fuller CD, Rosenthal DI, William WN Jr, Gunn GB, Beadle BM, Johnson FM, Morrison WH, Phan J, Frank SJ, Kies MS, Sturgis EM.

Cancer. 2016 Jun 1;122(11):1702-7. doi: 10.1002/cncr.29965. Epub 2016 Mar 28.


Outcomes for hypopharyngeal carcinoma treated with organ-preservation therapy.

Edson MA, Garden AS, Takiar V, Glisson BS, Fuller CD, Gunn GB, Beadle BM, Morrison WH, Frank SJ, Shah SJ, Tao R, William WN, Weber RS, Rosenthal DI, Phan J.

Head Neck. 2016 Apr;38 Suppl 1:E2091-9. doi: 10.1002/hed.24387. Epub 2016 Feb 27.


Proposed Staging System for Patients With HPV-Related Oropharyngeal Cancer Based on Nasopharyngeal Cancer N Categories.

Dahlstrom KR, Garden AS, William WN Jr, Lim MY, Sturgis EM.

J Clin Oncol. 2016 Jun 1;34(16):1848-54. doi: 10.1200/JCO.2015.64.6448. Epub 2016 Feb 16.


Relation between the level of lymph node metastasis and survival in locally advanced head and neck squamous cell carcinoma.

Xing Y, Zhang J, Lin H, Gold KA, Sturgis EM, Garden AS, Lee JJ, William WN Jr.

Cancer. 2016 Feb 15;122(4):534-45. doi: 10.1002/cncr.29780. Epub 2015 Nov 10.


Erlotinib and the Risk of Oral Cancer: The Erlotinib Prevention of Oral Cancer (EPOC) Randomized Clinical Trial.

William WN Jr, Papadimitrakopoulou V, Lee JJ, Mao L, Cohen EE, Lin HY, Gillenwater AM, Martin JW, Lingen MW, Boyle JO, Shin DM, Vigneswaran N, Shinn N, Heymach JV, Wistuba II, Tang X, Kim ES, Saintigny P, Blair EA, Meiller T, Gutkind JS, Myers J, El-Naggar A, Lippman SM.

JAMA Oncol. 2016 Feb;2(2):209-16. doi: 10.1001/jamaoncol.2015.4364.


Barriers to a Career Focus in Cancer Prevention: A Report and Initial Recommendations From the American Society of Clinical Oncology Cancer Prevention Workforce Pipeline Work Group.

Fabian CJ, Meyskens FL Jr, Bajorin DF, George TJ Jr, Jeter JM, Khan S, Tyne CA, William WN Jr.

J Clin Oncol. 2016 Jan 10;34(2):186-93. doi: 10.1200/JCO.2015.63.5979. Epub 2015 Nov 2.


Induction chemotherapy for oral cavity cancer patients: Current status and future perspectives.

Marta GN, William WN Jr, Feher O, Carvalho AL, Kowalski LP.

Oral Oncol. 2015 Dec;51(12):1069-75. doi: 10.1016/j.oraloncology.2015.10.009. Epub 2015 Oct 27. Review.


STAT3-mediated IGF-2 secretion in the tumour microenvironment elicits innate resistance to anti-IGF-1R antibody.

Lee JS, Kang JH, Boo HJ, Hwang SJ, Hong S, Lee SC, Park YJ, Chung TM, Youn H, Lee SM, Kim BJ, Chung JK, Chung Y, William WN Jr, Shin YK, Lee HJ, Oh SH, Lee HY.

Nat Commun. 2015 Oct 14;6:8499. doi: 10.1038/ncomms9499.


A Patient-Derived, Pan-Cancer EMT Signature Identifies Global Molecular Alterations and Immune Target Enrichment Following Epithelial-to-Mesenchymal Transition.

Mak MP, Tong P, Diao L, Cardnell RJ, Gibbons DL, William WN, Skoulidis F, Parra ER, Rodriguez-Canales J, Wistuba II, Heymach JV, Weinstein JN, Coombes KR, Wang J, Byers LA.

Clin Cancer Res. 2016 Feb 1;22(3):609-20. doi: 10.1158/1078-0432.CCR-15-0876. Epub 2015 Sep 29.


New DNA methylation markers and global DNA hypomethylation are associated with oral cancer development.

Foy JP, Pickering CR, Papadimitrakopoulou VA, Jelinek J, Lin SH, William WN Jr, Frederick MJ, Wang J, Lang W, Feng L, Zhang L, Kim ES, Fan YH, Hong WK, El-Naggar AK, Lee JJ, Myers JN, Issa JP, Lippman SM, Mao L, Saintigny P.

Cancer Prev Res (Phila). 2015 Nov;8(11):1027-35. doi: 10.1158/1940-6207.CAPR-14-0179. Epub 2015 Sep 4.


Outcomes of Cancer Patients Undergoing Percutaneous Pericardiocentesis for Pericardial Effusion.

El Haddad D, Iliescu C, Yusuf SW, William WN Jr, Khair TH, Song J, Mouhayar EN.

J Am Coll Cardiol. 2015 Sep 8;66(10):1119-28. doi: 10.1016/j.jacc.2015.06.1332. Erratum in: J Am Coll Cardiol. 2015 Nov 17;66(20):2269.


Induction chemotherapy prior to surgery with or without postoperative radiotherapy for oral cavity cancer patients: Systematic review and meta-analysis.

Marta GN, Riera R, Bossi P, Zhong LP, Licitra L, Macedo CR, de Castro Junior G, Carvalho AL, William WN Jr, Kowalski LP.

Eur J Cancer. 2015 Nov;51(17):2596-603. doi: 10.1016/j.ejca.2015.08.007. Epub 2015 Aug 26. Review.


Long-term results of a randomized phase III trial of TPF induction chemotherapy followed by surgery and radiation in locally advanced oral squamous cell carcinoma.

Zhong LP, Zhang CP, Ren GX, Guo W, William WN Jr, Hong CS, Sun J, Zhu HG, Tu WY, Li J, Cai YL, Yin QM, Wang LZ, Wang ZH, Hu YJ, Ji T, Yang WJ, Ye WM, Li J, He Y, Wang YA, Xu LQ, Zhuang Z, Lee JJ, Myers JN, Zhang ZY.

Oncotarget. 2015 Jul 30;6(21):18707-14.


Hedgehog Pathway Inhibition for Locally Advanced Periocular Basal Cell Carcinoma and Basal Cell Nevus Syndrome.

Ozgur OK, Yin V, Chou E, Ball S, Kies M, William WN, Migden M, Thuro BA, Esmaeli B.

Am J Ophthalmol. 2015 Aug;160(2):220-227.e2. doi: 10.1016/j.ajo.2015.04.040. Epub 2015 Apr 30.


A novel target for oral cancer chemoprevention? Notch quite, yet….

William WN Jr, El-Naggar AK.

Cancer Prev Res (Phila). 2015 Apr;8(4):262-5. doi: 10.1158/1940-6207.CAPR-15-0057. Epub 2015 Feb 24.


Prevention of tumor growth driven by PIK3CA and HPV oncogenes by targeting mTOR signaling with metformin in oral squamous carcinomas expressing OCT3.

Madera D, Vitale-Cross L, Martin D, Schneider A, Molinolo AA, Gangane N, Carey TE, McHugh JB, Komarck CM, Walline HM, William WN Jr, Seethala RR, Ferris RL, Gutkind JS.

Cancer Prev Res (Phila). 2015 Mar;8(3):197-207. doi: 10.1158/1940-6207.CAPR-14-0348. Epub 2015 Feb 13.


Evolutionary Action Score of TP53 Identifies High-Risk Mutations Associated with Decreased Survival and Increased Distant Metastases in Head and Neck Cancer.

Neskey DM, Osman AA, Ow TJ, Katsonis P, McDonald T, Hicks SC, Hsu TK, Pickering CR, Ward A, Patel A, Yordy JS, Skinner HD, Giri U, Sano D, Story MD, Beadle BM, El-Naggar AK, Kies MS, William WN, Caulin C, Frederick M, Kimmel M, Myers JN, Lichtarge O.

Cancer Res. 2015 Apr 1;75(7):1527-36. doi: 10.1158/0008-5472.CAN-14-2735. Epub 2015 Jan 29.


Relationship between tumor size and survival in non-small-cell lung cancer (NSCLC): an analysis of the surveillance, epidemiology, and end results (SEER) registry.

Zhang J, Gold KA, Lin HY, Swisher SG, Xing Y, Lee JJ, Kim ES, William WN Jr.

J Thorac Oncol. 2015 Apr;10(4):682-90. doi: 10.1097/JTO.0000000000000456.


Thymoma complicated by acquired amegakaryocytic thrombocytopenia and pure red cell aplasia.

Gay CM, William WN Jr, Wang SA, Oo TH.

J Natl Compr Canc Netw. 2014 Nov;12(11):1505-9.


Intratumor heterogeneity in localized lung adenocarcinomas delineated by multiregion sequencing.

Zhang J, Fujimoto J, Zhang J, Wedge DC, Song X, Zhang J, Seth S, Chow CW, Cao Y, Gumbs C, Gold KA, Kalhor N, Little L, Mahadeshwar H, Moran C, Protopopov A, Sun H, Tang J, Wu X, Ye Y, William WN, Lee JJ, Heymach JV, Hong WK, Swisher S, Wistuba II, Futreal PA.

Science. 2014 Oct 10;346(6206):256-9. doi: 10.1126/science.1256930.


Sleep-related breathing disorders in patients with tumors in the head and neck region.

Faiz SA, Balachandran D, Hessel AC, Lei X, Beadle BM, William WN Jr, Bashoura L.

Oncologist. 2014 Nov;19(11):1200-6. doi: 10.1634/theoncologist.2014-0176. Epub 2014 Oct 1.


A phase I/II study combining erlotinib and dasatinib for non-small cell lung cancer.

Gold KA, Lee JJ, Harun N, Tang X, Price J, Kawedia JD, Tran HT, Erasmus JJ, Blumenschein GR, William WN, Wistuba II, Johnson FM.

Oncologist. 2014 Oct;19(10):1040-1. doi: 10.1634/theoncologist.2014-0228. Epub 2014 Aug 28.


Optimizing surrogate end points for preoperative systemic therapies in non-small cell lung cancers.

William WN Jr, Swisher SG.

Ann Surg Oncol. 2014 Sep;21(9):2813-4. doi: 10.1245/s10434-014-3796-1. Epub 2014 May 16. No abstract available.


Targeting the epidermal growth factor receptor for head and neck cancer chemoprevention.

Mak MP, William WN Jr.

Oral Oncol. 2014 Oct;50(10):918-23. doi: 10.1016/j.oraloncology.2013.12.024. Epub 2014 Jan 10.


Pathological response after neoadjuvant chemotherapy in resectable non-small-cell lung cancers: proposal for the use of major pathological response as a surrogate endpoint.

Hellmann MD, Chaft JE, William WN Jr, Rusch V, Pisters KM, Kalhor N, Pataer A, Travis WD, Swisher SG, Kris MG; University of Texas MD Anderson Lung Cancer Collaborative Group.

Lancet Oncol. 2014 Jan;15(1):e42-50. doi: 10.1016/S1470-2045(13)70334-6. Review.


Epidemiology of head and neck squamous cell cancer among HIV-infected patients.

Dʼsouza G, Carey TE, William WN Jr, Nguyen ML, Ko EC, Riddell J 4th, Pai SI, Gupta V, Walline HM, Lee JJ, Wolf GT, Shin DM, Grandis JR, Ferris RL.

J Acquir Immune Defic Syndr. 2014 Apr 15;65(5):603-10. doi: 10.1097/QAI.0000000000000083.


HRAS mutations and resistance to the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in head and neck squamous cell carcinoma cells.

Hah JH, Zhao M, Pickering CR, Frederick MJ, Andrews GA, Jasser SA, Fooshee DR, Milas ZL, Galer C, Sano D, William WN Jr, Kim E, Heymach J, Byers LA, Papadimitrakopoulou V, Myers JN.

Head Neck. 2014 Nov;36(11):1547-54. doi: 10.1002/hed.23499. Epub 2014 Mar 20.


The role of systemic treatment before, during, and after definitive treatment.

Gold KA, Neskey M, William WN Jr.

Otolaryngol Clin North Am. 2013 Aug;46(4):645-56. doi: 10.1016/j.otc.2013.04.005. Epub 2013 May 25. Review.


Oral premalignancy: the roles of early detection and chemoprevention.

Foy JP, Bertolus C, William WN Jr, Saintigny P.

Otolaryngol Clin North Am. 2013 Aug;46(4):579-97. doi: 10.1016/j.otc.2013.04.010. Epub 2013 May 25. Review.

Supplemental Content

Loading ...
Support Center